Guidelines for acromegaly management: An update

S. Melmed; A. Colao; A. Barkan; M. Molitch; A. B. Grossman; D. Kleinberg; D. Clemmons; P. Chanson; E. Laws; J. Schlechte; M. L. Vance; K. Ho; A. Giustina

doi:10.1210/jc.2008-2421

Guidelines for acromegaly management: An update

S. Melmed^*, A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M. L. Vance, K. Ho, A. Giustina

^*Corresponding author for this work

Medicine, Endocrinology Division

Research output: Contribution to journal › Article › peer-review

656 Scopus citations

Abstract

Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. Participants: The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly. Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence. Conclusions: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.

Original language	English (US)
Pages (from-to)	1509-1517
Number of pages	9
Journal	Journal of clinical endocrinology and metabolism
Volume	94
Issue number	5
DOIs	https://doi.org/10.1210/jc.2008-2421
State	Published - May 2009

Funding

This study was sponsored by the Pituitary Society and the European Neuroendocrine Association and was supported by unrestricted grants from Ipsen and Tercica, Inc. Editorial assistance was provided by ESP BioScience. Disclosure Summary: A.C., D.C., E.L., J.S., and M.L.V. have nothing to declare. A.B. has consulted for Ipsen. M.M. has received research grants from Tercica and Ipsen and has consulted, received honoraria, and been a spokesperson for Tercica. A.B.G. has consulted for, served on advisory boards for, received honoraria from, and been a spokesperson for Ipsen and Novartis. D.K. has consulted for, served on advisory boards for, and received honoraria from Ipsen. P.C. has served on advisory boards for Novartis and has received honoraria from Novartis, Ipsen, and Pfizer. K.H. has consulted for Novartis and Ipsen. S.M. has consulted for Novartis and Ipsen and received a grant from Novartis. A.G. has consulted for Ipsen, Pfizer, and Italfarmaco and has received lecture fees from Novartis and Italfarmaco.

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1210/jc.2008-2421

Cite this

@article{eee7272026ba427d9b9e422444f15ac1,

title = "Guidelines for acromegaly management: An update",

abstract = "Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. Participants: The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly. Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence. Conclusions: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.",

author = "S. Melmed and A. Colao and A. Barkan and M. Molitch and Grossman, \{A. B.\} and D. Kleinberg and D. Clemmons and P. Chanson and E. Laws and J. Schlechte and Vance, \{M. L.\} and K. Ho and A. Giustina",

note = "Funding Information: This study was sponsored by the Pituitary Society and the European Neuroendocrine Association and was supported by unrestricted grants from Ipsen and Tercica, Inc. Editorial assistance was provided by ESP BioScience. Funding Information: Disclosure Summary: A.C., D.C., E.L., J.S., and M.L.V. have nothing to declare. A.B. has consulted for Ipsen. M.M. has received research grants from Tercica and Ipsen and has consulted, received honoraria, and been a spokesperson for Tercica. A.B.G. has consulted for, served on advisory boards for, received honoraria from, and been a spokesperson for Ipsen and Novartis. D.K. has consulted for, served on advisory boards for, and received honoraria from Ipsen. P.C. has served on advisory boards for Novartis and has received honoraria from Novartis, Ipsen, and Pfizer. K.H. has consulted for Novartis and Ipsen. S.M. has consulted for Novartis and Ipsen and received a grant from Novartis. A.G. has consulted for Ipsen, Pfizer, and Italfarmaco and has received lecture fees from Novartis and Italfarmaco. ",

year = "2009",

month = may,

doi = "10.1210/jc.2008-2421",

language = "English (US)",

volume = "94",

pages = "1509--1517",

journal = "Journal of clinical endocrinology and metabolism",

issn = "0021-972X",

publisher = "Endocrine Society",

number = "5",

}

TY - JOUR

T1 - Guidelines for acromegaly management

T2 - An update

AU - Melmed, S.

AU - Colao, A.

AU - Barkan, A.

AU - Molitch, M.

AU - Grossman, A. B.

AU - Kleinberg, D.

AU - Clemmons, D.

AU - Chanson, P.

AU - Laws, E.

AU - Schlechte, J.

AU - Vance, M. L.

AU - Ho, K.

AU - Giustina, A.

N1 - Funding Information: This study was sponsored by the Pituitary Society and the European Neuroendocrine Association and was supported by unrestricted grants from Ipsen and Tercica, Inc. Editorial assistance was provided by ESP BioScience. Funding Information: Disclosure Summary: A.C., D.C., E.L., J.S., and M.L.V. have nothing to declare. A.B. has consulted for Ipsen. M.M. has received research grants from Tercica and Ipsen and has consulted, received honoraria, and been a spokesperson for Tercica. A.B.G. has consulted for, served on advisory boards for, received honoraria from, and been a spokesperson for Ipsen and Novartis. D.K. has consulted for, served on advisory boards for, and received honoraria from Ipsen. P.C. has served on advisory boards for Novartis and has received honoraria from Novartis, Ipsen, and Pfizer. K.H. has consulted for Novartis and Ipsen. S.M. has consulted for Novartis and Ipsen and received a grant from Novartis. A.G. has consulted for Ipsen, Pfizer, and Italfarmaco and has received lecture fees from Novartis and Italfarmaco.

PY - 2009/5

Y1 - 2009/5

N2 - Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. Participants: The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly. Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence. Conclusions: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.

AB - Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. Participants: The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly. Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence. Conclusions: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.

UR - http://www.scopus.com/inward/record.url?scp=66149130384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149130384&partnerID=8YFLogxK

U2 - 10.1210/jc.2008-2421

DO - 10.1210/jc.2008-2421

M3 - Article

C2 - 19208732

AN - SCOPUS:66149130384

SN - 0021-972X

VL - 94

SP - 1509

EP - 1517

JO - Journal of clinical endocrinology and metabolism

JF - Journal of clinical endocrinology and metabolism

IS - 5

ER -

Guidelines for acromegaly management: An update

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this